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 Abstract 
 
Objectives: Heart rate variability (HRV) and haemodynamic response to exercise (i.e. peak 
cardiac power output) are strong predictors of mortality in heart failure. The present study 
assessed the relationship between measures of HRV and peak cardiac power output.  
Design: In a prospective observational study of 33 patients (age 54±16 years) with chronic 
heart failure with reduced left ventricular ejection fraction (29±11%), measures of the HRV 
(i.e. R-R interval and standard deviation of normal R-R intervals, SDNN) were recorded in a 
supine position. All patients underwent maximal graded cardiopulmonary exercise testing 
with non-invasive (inert gas rebreathing) cardiac output assessment. Cardiac power output, 
expressed in watts, was calculated as the product of cardiac output and mean arterial blood 
pressure. 
Results: The mean RR and SDNN were 837±166 and 96±29 ms, peak exercise cardiac 
power output 2.28±0.85 watts, cardiac output 10.34±3.14 l/min, mean arterial blood pressure 
98±14 mmHg, stroke volume 91.43±40.77 ml/beat, and oxygen consumption 19.0±5.6 
ml/kg/min. There was a significant but only moderate relationship between the RR interval 
and peak exercise cardiac power output (r=0.43, p=0.013), cardiac output (r=0.35, p=0.047), 
and mean arterial blood pressure (r=0.45, p=0.009). The SDNN correlated with peak cardiac 
power output (r=0.42, p=0.016), mean arterial blood arterial (r=0.41, p=0.019), and stroke 
volume (r=0.35, p=0.043).  
Conclusions: Moderate strength of the relationship between measures of HRV and cardiac 
response to exercise suggests that cardiac autonomic function is not good indicator of overall 
function and pumping capability of the heart in chronic heart failure.   
 
Key words: Heart Failure, Heart Rate Variability, Cardiac Power Output, Exercise 
Haemodynamics, Exercise Testing   
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 Introduction  
Heart failure is a clinical syndrome associated with reduced cardiac function and high 
morbidity and mortality rates [1]. Chronic heart failure patients demonstrate severe 
derangement of the autonomic nervous system characterised by chronic sympathetic 
hyperactivation, vagal withdrawal, resetting of the baroreflex sensitivity, and decreased 
peripheral and central responsiveness to adrenergic input [2, 3].  Chronic sympathetic 
activation alters heart rate variability (HRV) which is an accepted measure of cardiac 
autonomic regulation and is the analysis of variation in time intervals between heart beats. 
Overall HRV (i.e. beat-to-beat, R–R interval]) is reduced in chronic heart failure [3, 4], and 
is associated with significantly higher mortality rates [5, 6, 7]. Two commonly evaluated and 
presented time domain measures of HRV i.e. RR interval and the standard deviation of 
normal-to-normal (N-N) intervals (SDNN), are strong predictors of prognosis in chronic 
heart failure [5, 8, 9].  The SDNN  also appears to be associated with left ventricular ejection 
fraction [10].  
On another hand, cardiac power output (CPO) is a central hemodynamic measure that 
demonstrates overall function and pumping capability of the heart [11]. It is calculated as the 
product of simultaneously measured cardiac output and mean blood arterial pressure.  By 
incorporating pressure and flow domains of the cardiovascular system, CPO is an integrative 
measure of overall function and pumping capability of the heart [12]. Cardiac power output, 
measured at peak exercise, has been shown to be a most powerful predictor of prognosis and 
mortality in patients with chronic heart failure [13, 14].  
Whether autonomic regulation of the heart may be used as a surrogate measure of cardiac 
power output and haemodynamic response to exercise in chronic heart failure has not been 
investigated previously. Therefore, the aim of the present study was to evaluate the 
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 relationship between measures of heart rate variability, cardiac power output and 
haemodynamic response to exercise in patients with chronic heart failure.  
Methods 
Study Design and Patients  
The prospective observational study recruited 33 patients with chronic heart failure due to 
reduced left ventricular ejection fraction. Patients were on optimal medical management and 
their demographic and clinical features are presented in Table 1. Exclusion criteria were the 
inability to perform maximal graded cardiopulmonary exercise test, inability to exercise 
beyond anaerobic threshold, symptomatic angina limiting exercise, and unwillingness to 
provide a consent form. The study protocol was approved by the UK Health Research 
Authority - North East Tyne and Wear South Research Ethics Committee (reference: 
15/NE/0190). All patients provided written informed consent and all study procedures were 
in accordance to Declaration of Helsinki. 
Heart Rate Variability  
Upon arrival in the clinical physiology laboratory, patients’ weight and height were 
measured. Heart rate variability was measured and evaluated using the TF5 heart rate 
monitor and associated software (Advanced Medical Diagnostics Ltd., Leeds, UK). After 
fitting the patients with the TF5 chest strap in accordance with manufacturer’s instructions, 
patients had 5 minutes of recordings whilst in the supine position with controlled breathing 
(12 breaths per minute) using a previously validated protocol [15]. All R–R interval data 
were obtained with the automated algorithms available in the software. SDNN was 
calculated by calculating the standard deviation of N-N  interval as recommended by the 
Taskforce on HRV [4]. 
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 The 12 lead ECG electrodes were attached according to the standard lead configuration for 
exercise testing. Following a 5-min resting period while the patient sat on a chair, arterial 
blood pressure was assessed from the brachial artery by cuff sphygmomanometry.  
Haemodynamic Assessment  
Measurement of cardiac output was taken in a seated position using the inert gas rebreathing 
method (Innocor A/S, Innovision, Odense, Denmark) as previously described [16, 17]. The 
Innocor device employs a rebreathing system that briefly uses an oxygen-enriched mixture of 
an inert soluble gas (0.5% nitrous oxide) and an inert insoluble gas (0.1% sulphur 
hexafluoride) from a 4 L pre-filled anaesthesia bag. Photoacoustic analyzers measure gas 
concentrations during the rebreathing manoeuvre. Nitrous oxide concentration decreases 
during the rebreathing at a rate proportional to pulmonary blood flow, allowing estimation of 
cardiac output. Three to four respiratory cycles are needed to obtain a value for nitrous oxide 
washout. Acceptable reproducibility (i.e. coefficient of variation of <6%) of inert gas 
rebreathing method for estimating cardiac output at rest and during stress testing was 
previously confirmed in healthy individuals and patients with chronic heart failure [18, 19, 
20].  
The Innocor device also incorporates a breath-by-breath module to evaluate gas exchange 
variables (oxygen consumption and carbon dioxide production measured using an oxygen 
sensor and a photoacoustic gas analyser) and minute ventilation [21]. The gas sample line and 
airflow umbilical are connected to the respiratory valve unit. Measurement of pulmonary 
ventilation is performed by a pressure difference pneumotach. Carbon dioxide analysis is 
performed by using a photoacoustic gas analyser. Gas exchange data and ventilation analysis 
is performed and results presented by the Innocor software. 
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 After 3 min of measurements at rest, patients performed a maximal graded cardiopulmonary 
exercise test using semi-recumbent cycle ergometer, starting unloaded (0 watts) cycling, with 
workload increased at the rate of 10 watts per minute and cadence of 60 to 70 revolutions per 
minute. Continuous breath-by-breath sampling of respiratory gases and heart rate 
measurements were undertaken. Patients were instructed to give a warning approximately 30 
seconds before they felt they would end the exercise test to obtain a final cardiac output 
rebreathing measurement with arterial blood pressure taken simultaneously at the peak of 
exercise. Respiratory exchange ratio ≥1.05 was used as an objective indicator that a patient is 
approaching near maximal exertion and when rebreathing manoeuvre was initiated. 
The patient continued to exercise through the measurement and recovery phase was initiated 
after the rebreathing manoeuvre was complete.  
Calculations and Statistical Analyses 
The cardiac power output was calculated from the product of cardiac output and mean arterial 
pressure using the following equation [16] CPO = (QT × MAP) × K, where CPO is cardiac 
power output measured in watts, QT is cardiac output in litres per min, MAP is mean arterial 
pressure in millimetres of mercury, and K is the conversion factor (2.22 × 10−3). Mean 
arterial pressure was calculated as: DBP + 0.412 × (SBP − DBP), where SBP is systolic 
blood pressure and DBP is diastolic blood pressure [22].  
All statistical analysis was carried out using SPSS version 23.0 (SPSS, Chicago, Illinois). 
Before statistical analysis, data were checked for univariate and multivariate outliers using 
standard Z-distribution cut-offs and Mahalanobis distance tests, respectively. Normality of 
distribution was assessed using a Kolmogorov-Smirnov test. Student’s t-test was used to 
assess differences in measured variables in response to cardiopulmonary exercise testing. 
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 Nominal variables were evaluated using the Chi-square test. Pearson coefficient of 
correlation or Spearman’s rank correlation coefficient were used, as appropriate, to determine 
the relationships between variables. Multiple regression analyses were used to identify 
predictors of peak cardiac power output. Statistical significance was indicated if p < 0.05. All 
data are presented as mean ± SD unless otherwise indicated. 
 
Results  
 
Patient demographic and clinical characteristics are presented in Table 1. Heart rate 
variability measures obtained at rest with controlled breathing were: RR interval, 837±166 
ms, and SDNN, 96±29 ms.  
In response to exercise, patients significantly increased mean arterial blood pressure, cardiac 
output, cardiac power output, heart rate, stroke volume, and oxygen consumption as shown 
in Table 2. 
There was a significant positive relationship between the RR interval and peak exercise 
cardiac power output (Figure 1A), cardiac output (Figure 1B), and mean arterial blood 
pressure (Figure 1C), but no significant relationship between RR interval and stroke volume 
was found (Figure 1D). 
Similarly, there was a significant positive relationship between the SDNN and peak exercise 
cardiac power output (r=0.42, p=0.02), mean arterial blood pressure (r=0.41, p=0.02), and 
stroke volume (r=0.35, p=0.04), but no significant relationship was found between the 
SDNN and peak cardiac output (r=0.32, p=0.07). There was no a significant relationship 
between peak exercise O2 consumption and RR with (r=0.05, p=0.79) and SDNN (r=-0.02, 
p=0.93).  
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 Similarly, there was no significant relationship between anaerobic threshold, as a marker of 
submaximal functional capacity, and RR interval (r=0.02, p=0.83), and SDNN (r=-0.21, 
p=0.16).  
Measurements of cardiac function obtained at rest were not significantly correlated with RR 
interval and SDNN i.e. cardiac power output (r=0.08, p=0.66; and r=0.09, p=0.63), cardiac 
output (r=0.12, p=0.53; and r=0.3, p=0.09), heart rate (r=-0.29, p=0.14; and r=-0.32, p=0.12), 
or mean arterial blood pressure (r=0.03, p=0.88; and r=-0.17, p=0.35).  Stroke volume did 
not correlate with RR interval (r=0.26, p=0.15) but was significantly associated with SDNN 
(r=0.44, p=0.011).  
A multiple regression analyses revealed predictors of peak cardiac power output including 
RR interval and NYHA status and aetiology (ischaemic vs dilated cardiomyopathy), F= 4.7, 
p = 0.01, R2 =0.36. Furthermore analyses suggested that gender or medication regimen 
including therapy with ACE inhibitor and beta blocker was not significant determinants of 
cardiac power output (p=0.26). 
 
Discussion 
 
To the best of our knowledge, this is the first study to investigate the relationship between 
measures of cardiac autonomic function, peak cardiac power output and haemodynamic 
response to exercise in chronic heart failure. The major findings suggest moderate strength 
of the relationship measures of RR and SDNN and those of haemodynamic response to 
exercise including peak cardiac power output. This finding indicate that cardiac autonomic 
function is a weak indicator of overall function and pumping capability of the heart in 
chronic heart failure.   
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Cardiac power output is a valuable measure of overall function and pumping capability of 
the heart [11]. It has been independently associated with mortality and exercise capacity in 
heart failure patients [14, 23]. Peak exercise cardiac power output <2 watts is a strong 
predictor of mortality in chronic heart failure [12-14] with heart transplant candidates 
demonstrating values of <1.5 watts [18]. Cardiac power output also appears to correlate with 
heart failure severity and differentiate well during cardiac restoration using mechanical 
circulatory support [14, 16, 17]. In the present study which recruited heart failure patients 
NYHA class II-IV, peak cardiac power output ranged from 0.92-3.9 watts, further 
confirming that it can be used as an objective marker of disease severity in clinical practice.    
Previous investigation reported that commonly measured cardiopulmonary exercise testing 
variables are poor indicators of peak cardiac power in patients with heart failure [24]. 
Findings from the present study for the first time demonstrate the relationship between RR 
interval and SDNN with peak cardiac power output. Despite the fact that HRV was 
suggested a strong predictor of outcomes in heart failure and its measurement can be 
performed easily [6,7], the evaluation of HRV has not been impeded in the heart failure 
clinical practice perhaps due to limited potential to improve diagnosis, monitoring or heart 
failure severity. The present study supports the notion of HRV limited utility to predict 
cardiac response to exercise.     
 
Chronic heart failure manifests an overactivation of the sympathetic system and 
parasympathetic withdrawal. This derangement in heart rate variability is further associated 
with excessive levels of circulating catecholamines [25]. It is expected that sympathetic drive 
may improve cardiac contractility and response to exercise resulting in higher values of 
cardiac output, stroke volume, heart rate, blood pressure and cardiac power output. Our 
 results confirm the trend of positive relationship between HRV and exercise 
heamodynamics. This association may partially be explained by the role of peripheral 
chemoreceptors [26]. In heart failure, chemoreceptor sensitivity is increased in response to 
sympathetic overactivity and is associated with improved exercise capacity and measures of 
heart rate variability as previously documented [26, 27].  
 
Present study further suggest that heart rate variability was not significantly correlated with a 
traditional cardiopulmonary exercise testing variable such as peak oxygen consumption, 
despite it having been shown to be a strong predictor of mortality and disease severity in 
heart failure [1]. To some extent this should not come as a surprise considering that oxygen 
consumption can be influenced by multiple peripheral factors in patients with chronic heart 
failure [28].  Indeed muscle blood flow in response to exercise stress is compromised in 
heart failure [29]. A recent study highlights the role of peripheral factors in the context of 
heart failure such as anaemia, vascular stiffness and intrinsic skeletal muscle abnormalities 
(i.e. mitochondrial dysfunction) resulting in limited exercise capacity and reduced peak 
oxygen consumption [30]. 
In our study the cardiac power increase in response to exercise stress was due to an increase 
in cardiac output and mean arterial blood pressure. The increase in cardiac output was due to 
an increase in heart rate and stroke volume. The heart rate response to exercise is blunted in 
chronic heart failure and is often further suppressed by beta blockers [1]. As a compensatory 
response, one would expect an increase in stroke volume via the Frank-Starling mechanism. 
Although stroke volume can increase two-to-three times in response to exercise stress, 
patients with heart failure demonstrate a reduced cardiac reserve and inability to respond to 
exercise stress compared with other chronic conditions as we have recently demonstrated 
[31].  
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 Based on moderate positive relationship between HRV and exercise haemodynamics, it is 
reasonable to suggest that treatments shown to improve heart rate variability may also 
improve peak cardiac power output. For example, the use of beta- and aldosterone- receptor 
blockers and angiotensin-converting enzyme inhibitors are strategies shown to improve not 
only survival and exercise tolerance but also heart rate variability in chronic heart failure [32, 
33, 34]. However, their direct effect on haemodynamic response to exercise warrants further 
investigations.     
 
Limitations 
The present study is not without limitations. Although the sample size was moderate it was 
sufficient to identify significant relationship between measures of heart rate variability and 
cardiac response to exercise. In the present study we used a non-invasive (rebreathing) 
method for monitoring cardiac output which requires a patient familiarisation with the 
rebreathing manoeuvre and potential additional effort during peak exercise. However, the use 
of gold standard invasive methods (i.e. thermodilution) via the right heart catheterization was 
not indicated in our patients. Nonetheless, the inert gas rebreathing method has been shown to 
be valid and reliable for measuring cardiac output in chronic heart failure [14].   
Conclusions 
The present study is the first to define the relationship between cardiac autonomic function, 
cardiac power output and haemodynamic response to exercise in chronic heart failure. 
Although there was a significant positive relationship between the measures of heart rate 
variability and peak cardiac power output, the strength of this relationship was only 
moderate. It is therefore reasonable to suggest that cardiac autonomic function is not good 
indicator of overall function and pumping capability of the heart in chronic heart failure.   
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 Table 1 
 
Number of patients (N)  33 
Age (years)  64±9 
Time since Diagnosis (years) 8±3 
Male, N (%) 26 (79) 
Height (cm) 173±8 
Mass (kg) 83.4±16.1 
Body mass index (kg/m2) 28.0±5.4 
Left ventricular ejection fraction (%)  29±9 
New York Heart Association Class, N(%) 
II 9 (27) 
III 14 (42) 
IV 10 (31) 
Aetiology, N(%) 
Ischaemic heart disease 18 (55) 
Idiopathic dilated cardiomyopathy 11 (33) 
Myocarditis 2 (6) 
Viral 1 (3) 
Peri-partum cardiomyopathy  1 (3) 
Medications, N(%) 
Beta blockers 28 (85) 
Angiotensin converting enzyme inhibitors 19 (58) 
Angiotensin-II receptor blockers  9 (27) 
Mineralocorticoid receptor antagonist 16 (48) 
Statin 15 (45) 
Digoxin 5 (15) 
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 Table 2 
 
Variables   Rest Exercise P value 
Systolic blood pressure (mmHg) 111±20 141±29 <0.001 
Mean arterial pressure (mmHg) 85±10 98±14 <0.001 
Diastolic blood pressure (mmHg) 71±7 77±10 <0.050 
Cardiac output (L/min) 5.32±1.28 10.34±3.14 <0.001 
Cardiac power output (watts) 1.00±0.28 2.28±0.85 <0.001 
Heart rate (bpm) 71.09±14.19 121.73±27.71 <0.050 
Stroke volume (ml/beat) 77.83±23.47 91.43±40.77 <0.001 
Oxygen consumption  (ml/kg/min) 3.99±1.17 19.04±5.64 <0.001 
Oxygen consumption (L/min) 0.33±0.10 1.57±0.42 <0.001 
Respiratory exchange ratio 0.82±0.06 1.10±0.06 <0.001 
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